Combination approaches in IDH1-mutated AML
Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, presents evidence on combination approaches for patients with IDH1-mutated acute myeloid leukemia (AML). Dr Desai explains how subtypes, variants such as R132, and co-mutations such as NPM1 and FLT3 shape survival and drug responses. She discusses the potential of the IDH1 inhibitor olutasidenib, highlighting the upcoming Phase II study (NCT07153497) evaluating all-oral olutasidenib plus ASTX727 (decitabine-cedazuridine) and venetoclax in IDH1-mutated AML. She also highlights future questions around sequencing frontline treatments, including doublet versus triplet regimens. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
